non-small-cell lung cancer
Conditions
Interventions
cisplatin, docetaxel, bevacizumab, and pemetrexed
Sponsors
Okayama Lung Cancer Study Group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: pathologically proven non-squamous cell carcinoma stage IV or ineligibility as candidates for curative treatment aged 75 or less measurable tumor sites no prior chemotherapy no prior systemic anticancer therapy including palliative brain or bone irradiation within 2 weeks of proposed entry to this trial no prior thoracic irradiation to primary tumor no prior operation within 4 weeks of proposed entry to this trial ECOG PS of 0 to 1 appropriate organ function acquisition of written informed consent
Exclusion criteria
Exclusion criteria: pts with active co-morbidities including severe conditions of heart diseases, gastric ulcers, infections, uncontrollable diabetes, psychlogicai diseases, hypertension, active interstitial and hearing loss. pts with hemoptysis with 2.5mL or more bleeding tendency pts with radiological findings of tumor invasion to major vessels (i.e. aorta) and cavity lesion pts with bleeding tendency pts who need continuous use of antithrombotic agents pts with active other cancers that was detected within the past 5 years pts with massive pleural and cardiac effusion and ascites that need to be immediately treated pregnant women pts who need emergent irradiation
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS | — |
Countries
Japan
Contacts
Public ContactKatsuyuki Hotta
Okayama University Hospital Department of Respiratory Medicine
Outcome results
None listed